univers coverag
calendar event
investor tour visit heart healthcar facil bu tour
investor tour visit heart healthcar facil bu tour
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
deep dive support cpet trial design ralinepag pah caveat
bottom line given lack comfort investor cardiopulmonari exercis
test cpet metric use primari endpoint phase ralinepag
pulmonari arteri hypertens pah spoke medacorp specialist ahead
studi initi day octob expect provid
inform trial design due complex topic believ
ineffici market investor agre us arna cpet program
succeed may attract entri point share late stage program
becom better understood report combin kol insight analys cpet
medic literatur highlight potenti advantag pitfal undertak cpet studi
fda approv reiter op pt
need invest care plan train execut order control factor
could confound studi detect treatment effect
kol check suggest execut care cpet provid opportun break
efficaci ceil encount drug class
believ arna util cpet basi ralinepag approv could drive enthusiasm
among sophist academ clinician treat pah could permeat gener
prescrib commun histor challeng associ success execut cpet keep us
cautious optimist present inform strategi next day octob
noh assess reinforc valu potenti pt
 methodolog dcf use dr tgr
bottom line last week therav report posit top-line phase iia result
norepinephrin serotonin reuptak inhibitor nsri neurogen orthostat hypotens
noh data small care select studi clearli produc increas
blood pressur meaning symptom improv patient debilit hypotens
disord believ data provid proof-of-concept compound updat
compani model includ sale begin grow unadjust
late probabl develop success po po seem reason
given experiment natur design recent complet phase iia trial small size
oblig explor multipl dose longer durat much larger patient number phase
previous estim revenu base trajectori northera brand
drug us market noh replac patient-bas revenu forecast
therav revenu estim increas beyond account revis
forecast price target increas believ estim
conserv could gener significantli revenu northera provid
product continu show greater efficaci durabl effect
produc meaning durabl efficaci select noh patient
advanc phase next month like approv later
fire cylind rais pt increas estim
 methodolog ev/ebitda blend adj ebitda
bottom line inflect point transit high growth diversifi hcit
platform initi coverag june note precipic
becom high-growth hcit platform compani link stellar convers
lucia ceo jeff sherman cfo convinc
inflect point reiter op rate rais pt increas
estim take account faster-than-expect popul manag pm ramp better-
than-expect margin expans under-lev balanc sheet strong provid
compani flexibl acceler growth tuck-in acquisit think could add
 revenu ebitda next year best-
in-class data asset strong medicaid relationship view remain attract take-
target strateg buyer note verita back verscend recent announc acquisit
competitor cotv mp ebitda link
report stellar quarter beat revenu adj ebitda adj ep
rais revenu guidanc mm mm adj ebitda guidanc
 mm mm due one-tim settlement charg net incom
guidanc lower mm mm exhibit
rais revenu adj ebitda estim mm mm respect top
end guidanc rang
pm ice cake
room run pi
shift medicar advantag likewis support continu growth hmsi commerci
busi increas util pi pm product
under-lev balanc sheet strong provid compani flexibl
acceler growth tuck-in acquisit think could add revenu
 ebitda next year
oper leverag busi model continu invest advanc analyt led
valuat fuller believ still room run stock price price target
contempl ev/ebitda multipl blend adj ebitda
focu remain sustain makena franchis
use wacc termin growth rate
bottom line follow thursday earn call increment optimist
ferahem near/medium term growth trajectori remain cautious optimist
sustain makena franchis gain reason success far drive
switch subcutan sq autoinjector makena connect mcc program
manag note sq gain strong support mcc rx state dispens written
continu work payer drive support brand play next
month larg depend upon number gener enter market aggress
go market share remain cautious optimist maintain prior assumpt
sq retain share iqvia-report each singl item vial autoinjector
vs current believ appropri reflect stock current level reiter
mp rate pt
adjust non-gaap ep non-gaap ep calcul analyst includ contribut
cbr
tack new reimburs zemdri cuti
zemdri complic urinari tract cuti indic increment posit
drg system might narrowli cover cost treatment inclus
pharmaceut room board new supplementari reimburs widen
commerci opportun achaogen creat patient access zemdri rate akao
qtr outlook slightli improv pt
 methodolog pro forma w/bcr ep
bottom line deliv rev/ep ahead consensu second qtr bcr
belt increas rev/ep guidanc slightli encouragingli gm improv sequenti
focu area investor recent overal result leav us increment
confid bdx/bcr mid-singl digit top-lin growth prospect mid-teen double-digit ep
growth next year bcr integr unfold pt vs prior assum
trade premium large-cap med-tech diversifi peer given above-averag ep growth
potenti get construct name like greater convict upsid bcr synergi
forecast order argu bigger multipl premium large-cap med-tech diversifi vs
current ascrib turn price-to-earnings premium ep vs group reiter mp
bd stand-alone onward new co inclus bcr oper deal close
weekli iqvia im trend week end juli
bottom line note analyz iqvia formerli im script trend week end juli
harvoni epclusa vosevi mp mavyret mp zepati nr
hcv genvoya descovi odefsey biktarvi juluca gsk nr hiv tagrisso azn
nr lung cancer imbruvica abbv/jnj op zydelig venclexta abbv/rhhbi nr
hematolog malign ibranc nr kisqali nv nr verzenio nr breast
cancer xtandi zytiga prostat cancer cabometyx nr renal cell carcinoma
otezla celg op plaqu psoriasi psoriat arthriti cosentyx nv plaqu psoriasi
psoriat arthriti ankylos spondyl taltz plaqu psoriasi tremfya plaqu
psoriasi dupix sni nr/regn op eucrisa atop dermat kevzara sny/regn
rheumatoid arthriti tecfidera mp multipl sclerosi breo anoro incrus trelegi
gsk/inva nr chronic obstruct pulmonari diseas nucala gsk fasenra azn
asthma praluent sny/regn repatha mp entresto nv cardiovascular diseas
trulic jardianc basaglar toujeo soliqua sni tresiba xultophi ozemp
nvo nr diabet austedo teva huntington contrav orex nr obes ocaliva
mp primari biliari cholang intrarosa mp dyspareunia actemra rhhbi
immuno-oncolog aimovig migrain
pleas see bodi report detail weekli iqvia script
bottom line report provid updat week end juli key product
watch
ali brief doc look fairli benign major new find
bottom line fda brief document post on-line today appear balanc construct
view review thorough scrutin develop program
close appear overli critic develop program ali
amikacin liposom inhal solut data three vote question look fair balanc
us like result vote favor refractori mycobacterium avium complex label
expect panel member histori suggest ye vote vote like consist
expect reiter outperform
sale
bottom line ivti revenue y/i in-lin us management reiter
excess revenue outlook ultim think interim ceo scott flora far
need demonstr busi revenue stabil re-assess sale strategi
ensur consistent/sustain growth beyond manag cost better
expect fact compani plan becom focus end-market target use
direct vs indirect channel reach core/non-cor segment product bag expand includ
photonvu adapt ultim compani focu market women health breast
one enabl focus sale organ drive higher sale per account thu
posit decis vyxeo
vyxeo increment posit effect octob establish increment
reimburs payment equal vyxeo wac price per vial
averag max vial use medicar inpati set design expect
effect year allow recalibr appropri drg payment rate vyxeo
applic note averag case-weight standard charg
doubl ms-drg threshold amount payment would help bridg
differenti previou medacorp survey work physician feedback highlight
vyxeo abil acceler patient treatment outpati set first induct cycl remain
predominantli inpati event believ addit payment step toward
help econom work better hospit rate outperform
analysi discount rate termin growth
bottom line crysvita good start remain encourag us/eu sale could
favor posit continu posit trajectori gene therapi program could garner
investor interest approv compani product crysvita partner kyowa
hakko kirin khk link link investor focus launch ultragenyx remain tight
lip granular detail crysvita top-lin revenu khk earn report provid
posit indic uptak product line recent medacorp survey howev
sinc compani report earn differ exactli apples-to-appl read-through
like difficult despit report posit less desir updat
long-chain fatti acid oxid disorders/lc-faod believ event
ultragenyx report encourag updat program matter look forward
data across multipl program reiter outperform pt
revenu mm basic gaap ep present
even ride org acceler reiter op pt
 methodolog ep
bottom line organ revenue growth disappoint make even
back-end load organ growth acceler hit reiter full-year guidanc ultim
ep estim remain unchang still think credibl revenue growth acceler
stori territori neotract outperform turn organ
management execut choppi deliv pre-neotract organ growth accel goal
recent qtr natur rais question whether organ growth acceler quickli
hope neotract turn organ increas confid achiev lt org
growth commit much increas confid also think derail
trajectori either especi given think neotract upsid capabl make
basi point increment shortfal underli biz materi part
think enough levers/driv period drive hsd growth
deliv mid-teen ep growth margin improv base item entir
depend top line also believ upsid potenti above-consensu out-year
forecast consid model contempl meaning benefits/contribut repla
tfx lyophil freeze-dri fresh frozen plasma product develop collabor
 armi medic materi develop activ recent fast track fda
repres increment growth driver neotract sale addt restructur initi
addt reiter op pt goe vs previous base recent group multipl
contract sinc last updat
revenu mm ep present note valuat base pf ep
final ipp less bad fear cut
pharma result pharmedium turnaround progress pt
 methodolog ep
dcf valuat use discount rate lt growth rate
 methodolog dcf translat ev/sal
recap posit sign palynziq supplement strong base busi
sum-of-the-part dcf discount rate pipelin termin growth rate
new instrument help drive growth portfolio transform
market demand robust book ahead
ep
solid confid sharehold vote commentari turn corner
ep
revenu earn miss possibl rebound pt
 methodolog combin sale dcf analysi wacc lt
solid set modestli rais ep new pt
 methodolog price-to-earnings ep
recap oca settl pbc fda label updat nash data
 methodolog dcf analysi discount rate termin growth rate
recap pot inflect point adcom pudfa around corner
discount rate termin growth rate
lumateperon file immin focu shift new indic
 methodolog blend revenu multipl dcf analysi
discount rate termin growth rate
result mix weak book highlight shift roi-bas sale
rais estim pt blow-out ceo/cfo convo
 methodolog adj ep
lower slower hire major surpris post-preannounc
 methodolog ev/sal multipl sale estim
rais exparel estim pt
 methodolog dcf use wacc termin growth rate
fundament intact intern transit impact quarter
sale
eye adcom week unev qtr
analysi discount rate termin growth rate
break away solid commerci pipelin opportun firm
 methodolog averag price-to-earnings p/ dcf methodolog
focu shift medium term top-lin growth remain
ebitda multipl ebitda
recap in-lin quarter launch set drive momentum
outperform market cap price price target methodolog average
dcf ev/ sale
quiet time wait full luspatercept data expans muscl
analysi discount rate termin growth rate
aug aug orkambi kalydeo cystic fibrosi fda approv
thesi base continu captur cystic fibrosi cf patient subpopul
vertex success iter cf modul oral combin medicin
multipl near-term catalyst approach link
august fda approv orkambi treat cystic fibrosi cf children
year age expect
august look fda approv kalydeco treat cf infant
month age
later anticip multipl develop includ
phase result kalydeco cf infant month age
ema approv symdeko treatment homozyg patient
phase result symdeko cf children age year old
eu approv orkambi treat homozyg patient year age
also expect initi phase i/ii trial treatment beta thalassemia
europ sickl cell diseas respect
aug omadacyclin antibiot skin pneumonia adcom
key catalyst remain time-frame conven adcom aug
potenti approv oct time-frame could move stock meaning
view fda decis panel indic concern
link view panel public forum review posit risk/
benefit profil omadacyclin evidenc last nce antibiot pneumonia
sinc adcom conven
continu view data packag omadacyclin support approv
believ current level street underappreci valu omadacyclin
gain clariti key discuss topic brief document
releas publicli two busi day ahead adcom date
pdufa date expect octob
believ investor expect head ph data readout
low especi sinc lack clariti around requir approv
still discuss fda around data analysi plan studi
niemann-pick type np-c ultra-rar progress neurodegen genet
diseas occur bodi properli break cholesterol lipid
lead harm amount lipid accumul spleen liver brain
believ ph i/ii result encourag given breakthrough
statu drug fda prior comment bar approv like low
medacorp specialist spoke enthusiast current
treatment altern off-label use miglustat limit efficaci high ae
rate diarrhea abdomin pain nausea
forecast sale grow larg opportun
believ one sever pipelin asset critic offset
declin key franchis acthar inomax ofirmev face competit
come year posit regulatori execut increas investor
interest emerg pipelin
one regn import catalyst approv antibodi cemiplimab
cutan squamou cell carcinoma cscc
compani pdufa date octob research suggest first approv
checkpoint antibodi new indic typic come ahead pdufa date like
june juli cemiplimab estim
particularli true applic benefit breakthrough design
prioriti review case cemiplimab
regeneron also appear signal expect approv occur earlier
date confirm us commerci team readi launch product
immedi avail channel
project peak pos-adjust us cemiplimab sale
aug ci sharehold vote esrx merger
ci-esrx deal seen pro-competit manag regulatori risk although
potenti activist activ involv deal see link note
view sharehold vote import binari event expect ci stock trade
vote unsuccess
accord wall street journal carl icahn own less ci stock
plan vote deal link
howev remain skeptic sharehold vote deal absent anoth
credibl well-capit buyer ci
ci manag indic esrx best capit deploy opportun ci drive
afford better outcom across broad payor mix ci estim
synergi deal success see link ci meet analysi
link analysi link
continu view ci deep valu name patient investor combin
mid-august hire extern sale rep cologuard screen
cologuard highli under-penetr strong popul need
colorect cancer screen believ could deliv penetr
revenu longer term penetr ttm sale
recent analysi util leerink healthcar advanc analyt suggest
hire extern rep remain track complet mid-august earlier
timelin highlight
view revenu growth depend fast compani hire sale rep
particularli extern rep harder find hire intern one
turn drive new physician reorder catalyz growth exist physician order
rep hire faster abl reach new pcp aggress
abl serv exist account sooner and/or frequent -- ultim drive upsid
estim take month rep becom fulli product
result updat like earli august
call announc earlier-than-expect complet enrol
follow-up stemi short-term elev myocardi infarct feasibl studi
put data present like aha chicago pivot trial start
possibl earli time-frame sooner base estim
esposito et al publish result anim studi jacc support left
ventricular unload prior reperfus translat human would impli impella
success stemi reduc infarct size prevent late-stag onset
heart failur -- someth would clinic relev also cost effect
concurr editori jacc review clearli bullish implic
esposito studi potenti impella use stemi patient outcom
reproduc human primari mechan lv unload enorm benefit
reduc futur hf event patient acut mi note intervent cardiologist
may also need prepar modifi therapeut strategi mi
estim stemi year would
doubl exist address patient popul high risk pci cardiogen
believ data present american psychiatr associ confer
provid limit insight genesight endpoint
view test key mygn long-term top-lin growth potenti
drive revenu upsid reimburs mygn desir
current medicar rate
signific controversi alreadi surround reach potenti given
pt trial fail meet primari endpoint met secondari endpoint remiss
respons data may provid sub-
analysi patient fail chang view medacorp specialist payer
journal public expect june coverage/contract decis expect
announc beyond
link takeaway meet manag
regulatori settlement behavior health feder state agenc appear like
posit catalyst
negoti remain on-going manag optimist settlement reach
investig state feder regul year
settlement reserv increas pre-tax
sourc leerink research compani inform factset price prior day
ali link note pdufa orkambi cystic fibrosi age
fda adcom antimicrobi drug omadacyclin acut bacteri skin skin
structur infect absssi community-acquir bacteri pneumonia cabp
medcac panel t-cell therapi
fda public hear biosimilar silver spring md
pdufa teva fremanezumab cgrp migrain
fda adcom vaccin relat biolog product
pdufa dupix moder sever asthma adult adolesc
pdufa xyrem cataplexi excess daytim sleepi
pdufa revefanacin lama copd
pdufa bremelanotid hypoact sexual desir disord fda adcom
schedul
world congress cancer skin
european societi cardiolog esc
associ offici analyt chemist aoac
societi laparoendoscop surgeon minim invas surgeri week
intern network fatti acid oxid research manag
world congress pharmaci pharmaceut scienc fip
societi studi inborn metabol diseas ssiem symposium
bioprocess intern confer exhibit
advanc genom biolog technolog agbt precis meet
societi minim invas spine surgeri smiss annual forum
american societi hypertens joint w/ american heart associ aha
european migran headach trust intern congress ehmtic
american academi otolaryngolog head neck surgeri aao-hnsf
intern societi research iser biennial meet
intern associ studi pain iasp world congress pain
european academi dermatolog venereolog eadv
american societi surgeri hand assh
advanc genom biolog technolog agbt precis meet
associ vascular access annual scientif meet
heart failur societi america hfsa annual scientif meet
deadlin lpnt solicit altern acquisit propos
go live az
ivti md ttoo recent
updat pleas contact leerink repres wish review
biopharma preview gener pain women anti-infect
hcit distribut preview pocket opportun
medic suppli devic individu co preview cardio large-cap
 takeaway immuno-oncolog panel
 takeaway nash panel
biopharma lp hic takeaway ibd panel
 takeaway migrain panel
biopharma lp hic reimburs panel oncolog gene therapi target limit
 rova-t present show anoth rout failur experiment oncolog
adap -- flash manag convers highlight data pipelin progress
adap studi advanc cell dose posit safeti data pt
-- flash present highlight opportun colorect cancer
celg updat strengthen profil remark respons durabl
celg profil continu present outperform
 tazemetostat mesothelioma data opportun combin outperform
 success pamrevlumab lapc may depend endpoint paradigm shift
imdz -- flash event highlight imdz approach strategi outperform
 event highlight investig view forward ii data outperform
-- flash highlight encourag data biomark strategi gastric
-- flash updat demonstr continu safeti earli efficaci
note wild ride ahead aaic data could drive
 ctad medacorp call aducanumab abeta hypothesi
biopharma biopharma catalyst tracker import catalyst remain second half
 takeaway annual day
 biotech portfolio concentr explain multipl compress
 first apprais tax offer small benefit
 vertex alexion top pick
-- flash takeaway leerink day outperform
 eas data confirm durabl gocovri superior vs gener
 day preview late stage program turn launch mani
 takeaway annual day
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
 growth deal capac target market
biopharma praluent show mortal benefit lower take aim highest risk group
mdco -- flash inclisiran lesson fourier/odyssey may better
novob dc highlight nvo management roundtabl discuss boston market
medic devic ada dash make splash highlight recent
medic devic leerink healthcar confer panel devic penetr set
medic devic leerink leadership seri outset drive shift dialysi self-car
novob dc highlight nvo management roundtabl boston market perform
medic devic leerink healthcar confer panel devic penetr set
medic suppli devic initi takeaway sage robot continu gain
medic devic survey support market share re-gain assumpt
medic devices-cardiolog hr takeaway cabana unlik chang af practic
biopharma price right payer fail get drug class come
 stabil sell-sid price trend medic posit ug op outperform
hcit distribut fda take step improv competit distributor near trough
 acthar survey suggest faster eros payer pressur competitor entri
qure updat model higher price assumpt po pt
 price commerci updat fda approv burosumab/crysvita
 respit price yet friendli hill fda could
biopharma trump-azar puls call drug price blueprint limit current hh
 hemophilia price adjust reflect efficaci luxturna paradigm pt
 outlook move higher price clariti suggest possibl upsid pt
hcit distribut blueprint thorough pbm like abl manag rebat
hcit distribut outlin possibl drug price polici draconian
fear
 updat hemophilia price assumpt ad pomp program pt
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc outperform
celg qed ged late stage failur throw ibd bd strategi
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
 patent strategi come focu mitig biosimilar risk outpfrm outperform
 news patent decis one remind method use patent
 doubl extend patent horizon tecfidera
 investor sleep path ip protect pt
adap kol address controversi ahead multipl data readout outperform
 anoth setback ido outperform ideal combo still unclear
biopharma what immuno-oncolog takeaway
biopharma summari leerink immuno-oncolog roundtabl
celg anoth bet car-t probabl probabl sensibl even
 deep dive highlight oncolog focu strategi nash market perform
 highlight kol panel lung cancer io cell
celg anoth bet car-t probabl probabl sensibl even
biopharma might deton event look like screen pot match-
 sotp support current stock price where pipelin upsid market
 sotp suggest pipelin free even stock bounc market perform
 dupi miss-inventori demand trend intact partnership flail
biopharma viii partnership acquisit biopharma new top list
ci june ci cfo boston meet insight rais pt outperform
 aet bring comprehens member
dplo mid-mkt pbm acquisit complet strateg move market perform
esrx detail esrx deal term dplo may acquisit target
 evolv provid landscap initi outperform initi
outperform
 partnership valid local jaki gut de-risk develop path pt
 increas pt takeda collabor stock weak offer oppti
manag -- flash gov lose t-twx close without condit posit
pharmaci benefit manag t-twx approv bode pend ci-esrx cvs-
deal capac
-- contact leerink repres detail access podcast
 pnh survey-soliri still grow like switch monthli sc best
athn survey highlight slow market time take deal pt market
biopharma atop derm still without ped leerink dupi derm survey
 hiv survey rapid adopt biktarvi challeng outlook
hcit distribut ambulatori survey show slowdown replac market on-going
shift vbc
 vyxeo survey suggest outpati usag grow outperform
major medacorp survey lung cancer posit azn
medic devices-cardiolog tavr survey in-lin out-year trend quarter look
ew thv link link
medic suppli devic survey suggest may wait
medic devic survey support market share re-gain assumpt
 acthar survey suggest faster eros payer pressur competitor entri
 bone pick medacorp survey suggest solid crysvita adopt esp
medic devic survey direct posit mute hope
teva rais austedo sale analysi posit medacorp physician survey
 open ablat atriclip drive near term growth mi longer term
 differenti poc signific runway impli upsid pt
 ceo call focus growth outlook potenti upsid area lrp pt
outlook alpha opportun abound healthcar share
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight heart failur kol discuss
